ES2140215T3 - Metodos para inhibir la exportacion de proteinas sin secuencia conductora que emplean glicosidos cardiacos o agliconas de los mismos y derivados. - Google Patents

Metodos para inhibir la exportacion de proteinas sin secuencia conductora que emplean glicosidos cardiacos o agliconas de los mismos y derivados.

Info

Publication number
ES2140215T3
ES2140215T3 ES97906577T ES97906577T ES2140215T3 ES 2140215 T3 ES2140215 T3 ES 2140215T3 ES 97906577 T ES97906577 T ES 97906577T ES 97906577 T ES97906577 T ES 97906577T ES 2140215 T3 ES2140215 T3 ES 2140215T3
Authority
ES
Spain
Prior art keywords
methods
export
aglicones
proteins
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97906577T
Other languages
English (en)
Inventor
Robert Z Florkiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2140215T3 publication Critical patent/ES2140215T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA METODOS PARA INHIBIR LA EXPORTACION DE UNA PROTEINA SIN LIDER A PARTIR DE UNA CELULA PONIENDO EN CONTACTO LA CELULA CON UN GLICOSIDO CARDIACO O DERIVADO AGLICON. LAS PROTEINAS SIN LIDER INCLUYEN FGF-1, FGF-2, IL-1 AL}, IL-1 BE} Y FACTOR XIIIA. ESTOS METODOS SON UTILES EN EL TRATAMIENTO DE DIFERENTES ESTADOS, INCLUYENDO TUMORES Y DIABETES.
ES97906577T 1996-02-12 1997-02-12 Metodos para inhibir la exportacion de proteinas sin secuencia conductora que emplean glicosidos cardiacos o agliconas de los mismos y derivados. Expired - Lifetime ES2140215T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/599,895 US5891855A (en) 1996-02-12 1996-02-12 Inhibitors of leaderless protein export

Publications (1)

Publication Number Publication Date
ES2140215T3 true ES2140215T3 (es) 2000-02-16

Family

ID=24401543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97906577T Expired - Lifetime ES2140215T3 (es) 1996-02-12 1997-02-12 Metodos para inhibir la exportacion de proteinas sin secuencia conductora que emplean glicosidos cardiacos o agliconas de los mismos y derivados.

Country Status (9)

Country Link
US (4) US5891855A (es)
EP (2) EP0828497B1 (es)
JP (1) JPH11500454A (es)
AT (1) ATE183922T1 (es)
AU (1) AU706644B2 (es)
CA (1) CA2242245A1 (es)
DE (1) DE69700464T2 (es)
ES (1) ES2140215T3 (es)
WO (1) WO1997028808A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
US6083706A (en) * 1997-02-26 2000-07-04 Ciblex Corporation Inhibitors of leaderless protein export
US5910484A (en) * 1997-05-30 1999-06-08 The General Hospital Corporation Treatment of ischemic cardiac malfunction
GB9716273D0 (en) 1997-07-31 1997-10-08 Kimberly Clark Ltd Hand cleanser
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20010042069A (ko) * 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
EP1150687A2 (en) 1999-02-12 2001-11-07 Cellpath, Inc. Methods for anti-tumor therapy
KR20070118315A (ko) * 1999-04-21 2007-12-14 와이어쓰 폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
CA2445889A1 (en) * 2001-05-02 2002-11-07 University Of South Florida Vector system for selection of genes encoding secreted proteins and membrane-bound proteins
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
EP1513403B1 (en) * 2002-05-28 2017-02-15 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7560528B2 (en) * 2003-06-20 2009-07-14 Efthimios Ippikoglou Method of producing recombinant DNA molecules
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
DE102004036047A1 (de) * 2004-07-24 2006-02-23 Bioghurt Biogarde Gmbh & Co. Kg Physiologisch aktive Zusammensetzung
EP1789090A2 (en) * 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
ATE509630T1 (de) * 2004-09-02 2011-06-15 Bionaut Pharmaceuticals Inc Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
EP1812010A2 (en) * 2004-10-18 2007-08-01 BTG International Limited Use of na+/ k+-atpase inhibitors and antagonists thereof
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
JP5484735B2 (ja) * 2006-01-31 2014-05-07 ザ、ユニバーシティー、オブ、トレド Ｎａ／Ｋ−ＡＴＰアーゼリガンド
CN107235980A (zh) 2006-05-04 2017-10-10 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8283441B2 (en) 2006-10-31 2012-10-09 University Of Toledo Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases
WO2009064657A1 (en) * 2007-11-13 2009-05-22 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR101717301B1 (ko) * 2008-10-14 2017-03-16 네리엄 바이오테크놀로지, 인크. 강심 배당체의 추출방법 및 조성물
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102573469B (zh) 2009-09-16 2015-02-25 托莱多大学 Na/K-ATP酶配体、毒毛花苷G拮抗剂及其测试方法和用途
WO2011088208A1 (en) 2010-01-13 2011-07-21 The University Of Toledo Materials and methods related to sodium/potassium adenosine triphosphase and cholesterol
ES2654584T3 (es) 2010-01-15 2018-02-14 Suzhou Neupharma Co., Ltd Ciertas entidades químicas, composiciones y métodos
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2670763B1 (en) 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
CN102219821A (zh) * 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途
WO2013165924A1 (en) * 2012-04-29 2013-11-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5545623A (en) * 1994-06-10 1996-08-13 Akira Matsumori Method of inhibiting secretion of inflammatory cytokines
US5556963A (en) 1994-08-05 1996-09-17 Oklahoma Medical Research Foundation Synthesis of 4-alkoxy-N-acetylneuraminic acid
WO1996004921A1 (en) * 1994-08-13 1996-02-22 Hong Keun Chung TNFα-SECRETION INHIBITOR CONTAINING SYRINGIN OR ITS AGLYCONE
US5627195A (en) * 1995-04-11 1997-05-06 Massachusetts Eye And Ear Infirmary Treatment for ocular inflammation

Also Published As

Publication number Publication date
DE69700464T2 (de) 2000-04-06
US6281197B1 (en) 2001-08-28
EP0828497A1 (en) 1998-03-18
JPH11500454A (ja) 1999-01-12
US6107283A (en) 2000-08-22
US5891855A (en) 1999-04-06
EP0828497B1 (en) 1999-09-01
CA2242245A1 (en) 1997-08-14
ATE183922T1 (de) 1999-09-15
AU2123197A (en) 1997-08-28
EP0941733A3 (en) 1999-12-01
WO1997028808A1 (en) 1997-08-14
DE69700464D1 (de) 1999-10-07
AU706644B2 (en) 1999-06-17
EP0941733A2 (en) 1999-09-15
US6071885A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
ES2140215T3 (es) Metodos para inhibir la exportacion de proteinas sin secuencia conductora que emplean glicosidos cardiacos o agliconas de los mismos y derivados.
IT1225701B (it) Poltrona per abbronzatura
FI911326A0 (fi) Manipulering eller skada indikerande organ.
KR880700670A (ko) 알파-msh의 동족체의 국소적용으로 메라노싸이트를 자극시키는 방법 및 이에 사용될 수 있는 조성물
DK130388D0 (da) Olie-i-vand-emulsioner, deres fremstilling og anvendelse
TR23582A (tr) Ters akista yikama yapmaya mahsus birden fazla kademeli duezen ve bu duezene ait usul kademeleri
IT8921737A0 (it) Struttura di vela cosidetta ad ala.
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
NO874722D0 (no) Forgrenede kvaternaere polyoksalkylenblandingspolyestere, fremgangsmaate til deres fremstilling og deres anvendelse.
BR8700779A (pt) Derivado de 2-ciano-benzimidazol,composicao antifungica,processo para a preparacao e utilizacao do dito derivado,processo para o tratamento de vegetais,associacoes compreendendo tais derivados,utilizacao das ditas associacoes,composicao fungicida,processo para preparacao das ditas associacoes,compostos e derivados de anilina
NO901504L (no) Isolerings- og fjaerelementer eller klemmelementer for festing av skinner.
FI920872A0 (fi) Foerbaettringar i skyddshjaelmar eller i anslutning till dessa.
ES1008643Y (es) Mueble expositor de muestras de tejidos.
DE3886851D1 (de) Stroboskoplicht-Generator für insbesondere medizinische Zwecke.
DK95988A (da) Synergistisk, veterinaert praeparat og/eller foderpraeblanding og fremgangsmaade til fremstilling heraf
NO872885L (no) 1,3,5-tritianderivater og fremgangsmŸte for deres fremstilling.
DK538586A (da) Substituerede pyrazolin-5-oner, deres fremstilling og anvendelse
IT8920984A0 (it) Composizione per il trattamento della nevralgia erpetica acuta e la nevralgia post erpetica.
IT8840104A0 (it) Cannula per prelievi, particolarmente di tipo endometriale e/o endocervicale
ES1009377Y (es) Expositor perfeccionado para muestras cosmeticas.
IT214012Z2 (it) Connettore perfezionato per basi tripolari e/o simili.
NO894379D0 (no) Sammensetninger og fremgangsmaate for konservering eller farging av tre.
ES1008369Y (es) Soporte perfeccionado para barra de cortinajes.
IT209892Z2 (it) Apparecchio abbronzante con testa perfezionata.
DK517287A (da) Proevebehandlingsenhed

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 828497

Country of ref document: ES